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Chlamydia trachomatis is the most common cause of bacterial sexually transmitted disease in the United States, and it is
the leading cause of preventable blindness in the world (1–5).
Untreated, C. trachomatis infection in women can cause pelvic
inflammatory disease, which can lead to infertility and ectopic
pregnancy because of scarring of the ovaries and the Fallopian
tubes (6). Infection by the lymphogranuloma venereum (LGV)2
strain of C. trachomatis, which has become more common in
North America and Europe (7, 8), is characterized by swelling
and inflammation of the lymph nodes in the groin (9).
Chlamydiae are intracellular pathogens that preferentially
infect epithelial mucosa and have a biphasic infection cycle
(10). A metabolically inactive form, the elementary body,
infects the epithelial host cells through entry vesicles that avoid
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fusion with host cell lysosomes and develop into a membranebound inclusion (11–13). Despite their intravacuolar localization, chlamydiae are still able to acquire nutrients from the host
cell and interact with host-cell signaling pathways (13–23).
Within a few hours, the elementary bodies differentiate into
larger, metabolically active reticulate bodies, which proliferate
but are noninfectious. Depending on the strain of C. trachomatis, the reticulate bodies transform back into elementary bodies
after 1–3 days and are released into the extracellular medium to
infect other cells (11, 24, 25). Chlamydial species possess a type
III secretion (T3S) system that secretes bacterial virulence factors into host cell cytosol and may control interactions between
the inclusion and host-cell compartments (26).
Long before the adaptive immune response is activated,
infected epithelial cells produce proinflammatory cytokines
and chemokines, including interleukin (IL)-6, IL-8, and granulocyte-macrophage colony-stimulating factor (27), which
recruit neutrophils to the site of infection and activate other
immune effector cells. However, in many cases the immune
system fails to clear the infection, and the chronic release of
cytokines becomes a major contributor to the scarring and
damage associated with the infection (28 –30).
The innate immune response during C. trachomatis infection is initiated by chlamydial pathogen-associated molecular
patterns, including lipopolysaccharides, which bind to pattern
recognition receptors such as Toll-like receptors and cytosolic
NOD-like receptors (NLRs), ultimately promoting pro-inflammatory cytokine gene expression and secretion of the cytokine
proteins (31–37). However, secretion of the key pro-inflammatory cytokine IL-1␤ is tightly regulated (38). First, pro-IL-1␤ is
produced following activation of pattern recognition receptor,
and the precursor is then cleaved into the mature form by the
pro-inflammatory cysteine protease, caspase-1 (also known as
interleukin-1 converting enzyme or ICE). The mechanism by
which caspase-1 is activated in response to infection or tissue
damage was found to be modulated by a macromolecular protein complex termed the “inflammasome,” which consists of an
NLR family member, an adaptor protein (apoptosis-associated
speck-like protein containing a caspase activation recruitment
domain or ASC), and an inactive caspase-1 precursor (procaspase-1) (39, 40). Previous studies demonstrated that IL-1␤ is
produced in response to chlamydial infection in dendritic cells,
macrophages, and monocytes (41– 44). Moreover, C. trachomatis or Chlamydia caviae infection activates caspase-1 in epithelial cells or monocytes (43, 45, 46). However, whether
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Inflammasomes have been extensively characterized in
monocytes and macrophages, but not in epithelial cells, which
are the preferred host cells for many pathogens. Here we show
that cervical epithelial cells express a functional inflammasome.
Infection of the cells by Chlamydia trachomatis leads to activation of caspase-1, through a process requiring the NOD-like
receptor family member NLRP3 and the inflammasome adaptor
protein ASC. Secretion of newly synthesized virulence proteins
from the chlamydial vacuole through a type III secretion apparatus results in efflux of Kⴙ through glibenclamide-sensitive Kⴙ
channels, which in turn stimulates production of reactive oxygen species. Elevated levels of reactive oxygen species are
responsible for NLRP3-dependent caspase-1 activation in the
infected cells. In monocytes and macrophages, caspase-1 is
involved in processing and secretion of pro-inflammatory cytokines such as interleukin-1␤. However, in epithelial cells, which
are not known to secrete large quantities of interleukin-1␤,
caspase-1 has been shown previously to enhance lipid metabolism. Here we show that, in cervical epithelial cells, caspase-1
activation is required for optimal growth of the intracellular
chlamydiae.

Caspase-1 Activation Stimulates Growth of C. trachomatis

caspase-1 activation during chlamydial infection requires the
formation of an inflammasome remains unclear.
Previous studies have shown that different pathogens can
cause inflammasome-mediated caspase-1 activation in macrophages and monocytes (47). However, epithelial cells lining
mucosal surfaces are not only the preferred target for chlamydial infection and other intracellular pathogens but also play an
important role in early host immune response to infection by
secreting proinflammatory cytokines and chemokines (27).
Although epithelial cells are not known to secrete large
amounts of IL-1␤, inflammasome-dependent caspase-1 activation in epithelial cells is known to contribute to lipid metabolism and membrane regeneration in epithelial cells damaged by
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the membrane-disrupting toxin, aerolysin (48). As lipids are
sorted from the Golgi apparatus to the chlamydial inclusion
(13, 15, 49), we therefore investigated whether C. trachomatis
induces caspase-1 activation in epithelial cells via the assembly
of an inflammasome. We demonstrated that C. trachomatisinduced caspase-1 activation is mediated by an inflammasome
containing the NLR member, NLRP3. Several studies have
demonstrated the involvement of T3S apparatus in inflammasome-mediated caspase-1 activation by different pathogens in
macrophages and monocytes (50 –56). Therefore, we further
investigated the mechanism by which C. trachomatis triggers
the formation of the NLRP3 inflammasome. Our results
showed that metabolically active chlamydiae, relying on their
VOLUME 284 • NUMBER 39 • SEPTEMBER 25, 2009
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FIGURE 1. C. trachomatis induces caspase-1 activation in HeLa cells. HeLa cells were infected with C. trachomatis at an m.o.i. ⫽ 3 for 12, 24, and 36 h.
A, Western blot analysis of HeLa cell lysates was performed to monitor caspase-1 (Casp1) activation using an antibody that detects pro-caspase-1 (p45, upper
band) and active caspase-1 (p20, lower band). B, caspase-1 activation was quantified using fluorescent FLICACasp1 reagent and analyzed by flow cytometry.
Nonfluorescent cells were gated in the first log-decade, and the fluorescence intensity was proportional to the level of caspase-1 activation. C, column chart of
FLICACasp1 flow cytometry data, showing the % of cells with activated caspase-1 as a function of infection time. Error bars represent standard deviation (n ⫽ 3).
** indicate p ⬍ 0.01; *** indicate p ⬍ 0.001, compared with uninfected cells.
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wise, and incubated for the indicated times in an incubator at 37 °C
with 5% CO2. Treatment with
inhibitors or other reagents was
performed at the indicated times
and concentrations.
Generation of HeLa Cells Expressing shRNA—HeLa cells stably expressing shRNA against NLRP3 and
ASC were obtained by transducing
HeLa cells with lentiviral particles.
The sequences 5⬘-CCGGGCGTTAGAAACACTTCAAGAACTCGAGTTCTTGAAGTGTTTCTAACGCTTTTTG-3⬘ for human NLRP3
(Sigma; catalog number NM_004895)
and 5⬘-CCGGCGGAAGCTCTTCAGTTTCACACTCGAGTGTGAAACTGAAGAGCTTCCGTTTTTG-3⬘ for human ASC (Sigma;
catalog number NM_013258) were
FIGURE 2. C. trachomatis-induced caspase-1 activation requires NLRP3 inflammasome. A, HeLa cells were
stably transfected with shRNAs that target NLRP3 or ASC, and mRNA expressions of NLRP3 (left panel) and ASC used separately to silence gene
(right panel) were quantified by real time PCR and compared with wild type (WT) and nontarget control (sh Ctrl). expression following the manuInset, Western blot analysis of wild type HeLa cells, cells treated with nontarget control, and cells treated with facturer’s instructions. Nontarget
shNLRP3, confirming decreased expression of the NLRP3 protein after mRNA knockdown. Western blot was
performed with an anti-NLRP3 antibody, which detects the 118-kDa protein. B, NLRP3, ASC, or nontarget shRNA control cells were also gencontrol knockdown HeLa cells were infected with L2 at an m.o.i. ⫽ 3 for 24 h, and C. trachomatis-induced erated using an irrelevant sequence
caspase-1 activation was measured by FLICACasp1. The fold increase in caspase-1 activation in infected nontar(Sigma; catalog number SHC002V).
get controls, shNLRP3-treated cells, and shASC-treated cells with respect to uninfected cells was compared
FLICA Staining—During the last
with the increase in 24 h-infected wild type cells. Error bars represent standard deviation of an experiment
performed in triplicate on three separate occasions. ** indicates p ⬍ 0.01; *** indicates p ⬍ 0.001.
hour of incubation, cells were
labeled with FAM-YVAD-fmk
T3S apparatus, cause K⫹ efflux, which in turn leads to forma- caspase-1 FLICATM kit (Immunochemistry, Bloomington, IN),
tion of reactive oxygen species (ROS) and ultimately NLRP3- which binds activated caspase-1. Flow cytometric analysis was
dependent caspase-1 activation. Epithelial cells do not typically performed according to manufacturer’s manual. In brief, cells
secrete large amounts of IL-1␤; instead, caspase-1 activation in were detached using TrypLETM Express (Invitrogen) and then
cervical epithelial cells contributes to development of the incubated with 1⫻ FLICA for 1 h followed by two washes and
analyzed with a Guava EasyCyte (Guava Technologies, Haychlamydial inclusion.
ward, CA).
EXPERIMENTAL PROCEDURES
Western Blotting—Samples were lysed using RIPA Lysis
Cells, Bacteria, and Chemical Reagents—Cervical epithelial Buffer (Millipore) and loaded onto a 15% SDS-polyacrylamide
cells (HeLa 229 cells) and the LGV/L2 strain of C. trachomatis gel and then transferred to a polyvinylidene difluoride memwere obtained from American Type Culture Collection brane (Millipore). Blots were blocked for 1 h with 5% (w/v)
(ATCC). HeLa cells were cultured in a humidified incubator at nonfat dried milk in TBST. The membrane was incubated over37 °C with 5% CO2 in Dulbecco’s modified Eagle’s medium night at 4 °C with rabbit anti-human caspase-1 antibody (Mil(Dulbecco’s modified Eagle’s medium/F-12) (Invitrogen) sup- lipore) and then incubated again with conjugated anti-rabbit
plemented with 10% heat-inactivated fetal calf serum (Invitro- IgG horseradish peroxidase (Millipore). For confirmation of
gen), and 10 g/ml gentamycin (Omega Scientific, Tarzana, NLRP3 depletion by RNA interference, a 9% gel was used,
CA). The number of bacterial inclusion forming units was and the blot was incubated with rabbit anti-human NLRP3
determined as described previously (18). N-Acetylcysteine antibody (Sigma; catalog number HPA012878). Immunore(NAC), glibenclamide, penicillin G, and cycloheximide were active proteins were detected with ECL Plus Western blotfrom Sigma. KCl was from Fisher; chloramphenicol was from ting detection reagents (Amersham Biosciences) using a gel
Calbiochem, and Z-YVAD-fmk was from Biovision (Mountain doc system (Bio-Rad).
Measurement of Production of ROS—Cells were labeled with
View, CA). Z-WEHD-fmk was purchased from R & D Systems
(Minneapolis, MN). INPs (0341 and 0406) were kind gifts from the cell-permeant ROS indicator dihydrocalcein-AM (Molecular Probes, Eugene, OR), following the manufacturer’s instrucDr. Pia Keyser (Innate Pharmaceuticals, Umeå, Sweden).
Cell Culture, Infection, and Treatments—HeLa cells growing tions. Briefly, cells were plated in phenol red-free Dulbecco’s
at 50% confluency on tissue culture flasks (Costar, Corning, modified Eagle’s medium (Invitrogen) and then infected and/or
NY) were infected with the LGV/L2 strain of C. trachomatis at treated for the indicated times. Cells were loaded with 10 M
a multiplicity of infection (m.o.i.) of 3.0, unless specified other- dihydrocalcein-AM in phosphate-buffered saline for 45 min at
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RESULTS
Chlamydia-mediated Caspase-1 Activation in Epithelial
Cells Requires the NLRP3 Inflammasome—To characterize
caspase-1 activation during C. trachomatis infection, we
infected human cervical epithelial (HeLa) cells with C. trachomatis (L2) at a multiplicity of infection (m.o.i.) of 3 for 12, 24,
and 36 h. The 45-kDa procaspase-1 was cleaved into the active
20-kDa caspase-1 at 24 h post infection, and processing was
further increased at 36 h post infection, as shown by the disappearance of the procaspase-1 zymogen and the concomitant
appearance of the active caspase-1 (Fig. 1A). Similar results
were obtained when we quantified caspase-1 activation in HeLa
cells using a cell-permeable fluorescent reagent, FLICACasp1,
which can specifically bind to the active form of caspase-1 (Fig.
1, B and C). Caspase-1 activation was barely noticeable at 12 h
post infection but became significant after a day of infection
(Fig. 1C), in agreement with recent studies (45).
Next we sought to determine whether an inflammasome may
be required for caspase-1 activation. The adaptor protein ASC
can be coupled to different NLR family members and therefore
seemed likely to play a role in inflammasome activation during
C. trachomatis infection. As IPAF (also known as NLRC4 (57))
was shown in previous studies to recognize mainly bacterial
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FIGURE 3. Caspase-1 activation following C. trachomatis infection is
caused by Kⴙ efflux and ROS production. A, HeLa cells were infected with C.
trachomatis at an m.o.i. ⫽ 3 for 0, 12, 16, 20, and 24 h, and intracellular ROS
levels were measured with the fluorescent dihydrocalcein reagent and analyzed by flow cytometry. Data are plotted as a line chart. B and C, HeLa cells
were infected or not with C. trachomatis at an m.o.i. ⫽ 3 for 24 h, and treated
or not with 10 mM NAC, 50 M glibenclamide (Gli), 70 mM KCl during the last
15 h of infection, or 60 g/ml chloramphenicol (Chl), 100 g/ml penicillin
(Pen), 10 g/ml cycloheximide (Cyc) during the last 6 h of infection. ROS production was quantified with dihydrocalcein (B), or caspase-1 activation was
measured with FLICACasp1 (C). Error bars represent standard deviation from at
least three separate experiments. * indicates p ⬍ 0.05; *** indicates p ⬍ 0.001,
compared with uninfected cells (A) or untreated infected cells (B and C).

flagellin (58, 59), which is not expressed in the chlamydial
genome (60), we focused our initial attention on NLRP3 (also
known as cryopyrin and Nalp3 (57)).
A role for either ASC or NLRP3 during chlamydial infection
was determined by silencing NLRP3 or ASC by shRNA in HeLa
cells. mRNA expression of either inflammasome component
was significantly reduced in comparison with nontarget
shRNA, as measured by real time PCR (Fig. 2A), although
higher levels of NLRP3 protein depletion were observed by
Western blotting (Fig. 2A). Consistent with a role for the
NLRP3 inflammasome in caspase-1 activation, individual
knockdown of NLRP3 or ASC caused a reduction of ⬃50% in
the activation of caspase-1 after 24 h of C. trachomatis infecVOLUME 284 • NUMBER 39 • SEPTEMBER 25, 2009
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37 °C, then recovered in growth media for 20 min, and finally
analyzed by flow cytometry with a Guava EasyCyte.
RNA Isolation and Real Time PCR—mRNA was isolated
from HeLa cells using the Qiagen RNeasy kit (Qiagen, Valencia,
CA) following the manufacturer’s instructions, and total RNA
was converted into cDNA by standard reverse transcription
with Taqman威 reverse transcriptase kit (Applied Biosystems,
Foster City, CA). Quantitative PCR was performed with 1:50 of
the cDNA preparation in the Mx3000P (Stratagene, La Jolla,
CA) in a 25-l final volume with Brilliant QPCR master mix
(Stratagene). The primers for human GAPDH were 5⬘-CTTCTCTGATGAGGCCCAAG-3⬘ forward and 5⬘-GCAGCAAACTGGAAAGGAAG-3⬘ reverse. Primers for human NLRP3 were
5⬘-CTTCCTTTCCAGTTTGCTGC-3⬘ forward and 5⬘-TCTCGCAGTCCACTTCCTTT-3⬘ reverse. Primers for human ASC
were 5⬘-AGTTTCACACCAGCCTGGAA-3⬘ forward and
5⬘-TTTTCAAGCTGGCTTTTCGT-3⬘ reverse. Real time PCR
included initial denaturation at 95 °C for 10 min, followed by 40
cycles of 95 °C for 30 s, 55 °C for 1 min, 72 °C for 1 min, and one
cycle of 95 °C for 1 min, 55 °C for 30 s, 95 °C for 30 s.
Chlamydia Quantitation and Fluorescence Microscopy—Following 24 h of infection, cells were harvested using a cell
scraper, frozen at ⫺80 °C, thawed, and thoroughly vortexed
before titrating on 50% confluent HeLa cells. Cells were then
stained by Hoechst stain (Sigma) and anti-chlamydial antibody
(Argene, North Massapequa, NY), mounted on slides, and
quantified by immunofluorescence on a wide field fluorescence
microscope (Leica, Deerfield, IL).
Statistical and Flow Cytometric Analyses—The statistical
analysis was performed using GraphPad Instat software
(GraphPad Software Inc, La Jolla, CA) by Student’s t test and
was considered significant at p ⬍ 0.05. Flow cytometry data
were analyzed using FlowJo威 software (Tree Star Inc, Ashland,
OR).
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dihydrocalcein, to measure intracellular ROS production. Similarly to
the time course for caspase-1 activation, there was essentially no ROS
production during the first 12 h of
chlamydial infection, but ROS production increased at 20 h post infection and continued to increase at
24 h post infection. However, unlike
the case for caspase-1 activation,
ROS levels returned to basal levels
at 36 h post infection (Fig. 3A).
To confirm whether chlamydiainduced ROS production may be
involved in activation of caspase-1,
we used the anti-oxidant NAC,
which was previously shown to
inhibit caspase-1 activation and
NLRP3 assembly (61, 63). Interestingly, the antioxidant NAC significantly diminished both ROS production and caspase-1 activation
induced by 24 h of chlamydial infection (Fig. 3, B and C), suggesting that
ROS production is upstream from
caspase-1 activation.
Besides ATP binding to the purinergic receptor, P2X7, the NLRP3
inflammasome can be activated by
ligands as varied as asbestos, alum,
monosodium urate, bacterial toxins, and K⫹ ionophores (64, 65).
What all of these disparate ligands
have in common is their ability to
induce K⫹ efflux from cells (63, 66).
FIGURE 4. Chlamydial T3S is responsible for ROS production and caspase-1 activation. HeLa cells were Given that an older study had
infected or not with C. trachomatis at an m.o.i. ⫽ 3 for 24 h and treated or not with 4, 16, or 25 M T3S shown that chlamydial infection
inhibitor (INP0341) or 25 M control INP (INP0406) for 9 h. ROS production was quantified by staining cells causes loss of intracellular potaswith dihydrocalcein (A), or caspase-1 activation was measured by staining cells with FLICACasp1 (B). Error
⫹
bars represent standard deviation of at least three separate experiments. * indicates p ⬍ 0.05; ** indicates sium (67), we examined whether K
p ⬍ 0.01; *** indicates p ⬍ 0.001, compared with infected untreated cells.
efflux results in ROS production
and/or caspase-1 activation during
tion, when compared with wild type HeLa cells or cells that chlamydial infection. Indeed, specifically blocking potassium
were transfected with nontarget shRNA (Fig. 2B). The reduc- channels with glibenclamide or limiting K⫹ release by addition
tion of caspase-1 activation was not complete (Fig. 2B) and was of extracellular potassium (KCl) was able not only to signifisimilar to the level of mRNA depletion by shRNA but lower cantly reduce caspase-1 activation but also to diminish ROS
than the level of NLRP3 protein depletion (Fig. 2A). These production induced by 24 h of infection with C. trachomatis
results imply that C. trachomatis infection induces caspase-1 (Fig. 3, B and C). Thus, our results demonstrate that C. trachoactivation through a process that requires, at least partially, the matis infection leads to loss of intracellular potassium, which in
assembly of the NLRP3 inflammasome.
turn causes production of ROS and subsequently caspase-1
Chlamydia-induced Caspase-1 Activation Is Caused by ROS activation.
Production as a Result of K⫹ Efflux—We investigated the mechChlamydial Protein Synthesis and the T3S System Are
anism by which C. trachomatis induces caspase-1 activation in Required for ROS Production and Caspase-1 Activation—To
HeLa cells. Previous studies have shown that ATP-dependent further investigate the mechanism by which Chlamydia actiROS production in macrophages can activate caspase-1 (61), vates caspase-1, we explored the possibility that chlamydiae
and that asbestos and silica can activate the NLRP3 inflamma- may secrete proteins into the host cells via T3S, leading to
some by increasing ROS production (62, 63). We therefore ROS production and activation of caspase-1. We first
evaluated whether C. trachomatis increases ROS production in checked whether chlamydial protein synthesis is important
HeLa cells, using a commercially available fluorescent reagent, for ROS production and caspase-1 activation during infec-
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unlike INP0406, significantly diminished caspase-1 activation
after 24 h of C. trachomatis infection (Fig. 4B). These results highlight the need for chlamydial T3S
in causing ROS production and
the subsequent activation of
caspase-1.
Caspase-1 Activation Is Required
for Efficient Development of the
Chlamydial Inclusion—NLRP3-dependent caspase-1 activation during plasma membrane damage
because of treatment with the bacterial toxin, aerolysin, has been
shown to play an indispensable role
in promoting lipid synthesis and
membrane repair (48). As this process also involved K⫹ efflux from the
toxin-treated cells, we investigated
the possibility that caspase-1 activation may be required for efficient
chlamydial infection. For this purpose, epithelial cells were infected
with C. trachomatis at an m.o.i. of
3 for 24 h and treated with the
irreversible caspase-1 inhibitor
Z-YVAD-fmk or the caspase-1/
caspase-5 inhibitor Z-WEHD-fmk
for the last 15 h of infection (the
inhibitors were added after 9 h post
infection). When the chlamydiae
were retitrated on a fresh monolayer of epithelial cells, a dramatic
decrease in the infectious activity of
the chlamydiae was observed, especially in cell samples that were
treated with the caspase-1/
caspase-5 inhibitor (Fig. 5A). FurFIGURE 5. Caspase-1 activation is required for efficient C. trachomatis infection. HeLa cells were infected thermore, addition of either inhibiwith C. trachomatis at an m.o.i. ⫽ 3 for 24 h and treated or not with two different caspase inhibitors as follows: tor had a remarkable effect on the
100 M caspase-1 inhibitor (Z-YVAD-fmk) or 100 M caspase-1/caspase-5 inhibitor (Z-WEHD-fmk) at 9 h post
infection. A, cells were harvested and retitrated on a fresh monolayer of HeLa cells for 24 h and stained with chlamydial inclusions; smaller, fragHoechst stain for DNA and anti-chlamydial antibody, and infected cells were counted. B, cells were stained mented inclusions were observed in
with Hoechst stain (blue) and anti-chlamydial antibody (green) and visualized on a fluorescence micro- the epithelial cells treated with
scope. Ctrl, control. Error bars represent standard deviation of three separate experiments. ** indicates p ⬍
either inhibitor (Fig. 5B). These
0.01; *** indicates p ⬍ 0.001, compared with infected untreated cells.
results suggest that caspase-1 actition. Indeed, chloramphenicol (chlamydial protein synthesis vation is required for efficient chlamydial infection.
inhibitor), but neither penicillin (inhibitor of chlamydial
division) nor cycloheximide (host cell protein synthesis DISCUSSION
inhibitor), was able to significantly decrease ROS production
Processing and secretion of IL-1␤ and IL-18 require the
and caspase-1 activation following 24 h of infection with C. activity of caspase-1, which in turn is activated following assemtrachomatis (Fig. 3, B and C). To determine whether the bly of an inflammasome (37). Infection of monocytes and macnewly synthesized bacterial proteins must be secreted, we rophages by Chlamydia in vitro leads to IL-1␤ secretion, and a
used a chemically synthesized compound that can inhibit requirement for caspase-1 was shown (43, 45, 46, 69). This sugchlamydial T3S (INP0341) and a closely related control com- gests that an inflammasome is assembled in monocytes and
pound INP (INP0406) (68). INP0341, but not INP0406, was macrophages during chlamydial infection.
able to abrogate Chlamydia-induced ROS production in a
However, the preferred host cells for most chlamydial species
dose-dependent manner (Fig. 4A). Moreover, INP0341, and strains are epithelial cells. More specifically, sexually trans-
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FIGURE 6. C. trachomatis triggers inflammasome-mediated caspase-1
activation through T3S-induced Kⴙ efflux and ROS production. Following infection, chlamydiae inject virulence factors via the T3S apparatus into
the host cell cytosol, causing loss of intracellular potassium and resulting in
the production of ROS. Elevated ROS levels trigger the assembly of the NLRP3
inflammasome, which subsequently activates caspase-1. Activated caspase-1
plays a role in lipid metabolism and glycolysis and enhances development of
the chlamydiae.

monocytes (39) and the expression of both caspases in cervical
epithelial cells (72). Although Z-WEHD-fmk also affects
caspase-4, it may also be a more effective caspase-1 inhibitor
than Z-YVAD-fmk (73). During the course of this study,
another laboratory reported that Z-WEHD-fmk can decrease
chlamydial infection in epithelial cells (74). Thus, growth of the
inclusion requires fragmentation of the Golgi apparatus, which
is because of proteolytic cleavage of a Golgi matrix protein,
Golgin-84. Blocking Golgin-84 cleavage with Z-WEHD-fmk
prevents Golgi fragmentation and inhibits lipid acquisition and
maturation of the chlamydial inclusion (74).
In uninfected cells, caspase-1 can directly cleave 41 proteins, including chaperones, cytoskeletal proteins, glycolytic
enzymes, and translation machinery proteins (71). Characterization of NLRP3-dependent caspase-1 activation during
chlamydial infection is therefore bound to uncover other effects
of infection on host-cell functions, which may include energy
metabolism and cytoskeletal integrity.
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